Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

What Was Tested

Researchers studied Teriparatide in this randomized controlled trial publication.

The researchers report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment.

Prior therapy does not adversely affect the response to teriparatide treatment.

Who Took Part

According to the abstract, 758 women were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

The researchers conducted a prospective, open-label, 24-month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment-naïve) who had at least one post-baseline bone marker determination.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Teriparatide study did not mask who received what.

The researchers measured procollagen type I N-terminal propeptide (PINP), bone-specific alkaline phosphatase (b-ALP), and total alkaline phosphatase (t-ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.

What Was Measured

Topics PubMed links to this paper include Alkaline Phosphatase, Biomarkers, Bone Density, Bone Density Conservation Agents, Drug Substitution, Femur Neck and Hip Joint.

What This Means in Plain Language

The paper is a randomized and open-label study of Teriparatide in 758 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.